Trending Topic

Musculoskeletal AI image
16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Samantha Cooray, Alexander Deng, Tim Dong

There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an example of inflammatory arthritis), connective tissue disease (CTD), Ehlers–Danlos syndrome (EDS) and musculoskeletal surgical interventions. […]

Alan J. Kivitz, ACR 2022: A phase 2 trial of dazodalibep in rheumatoid arthritis

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 21st 2022

Dazodalibep is a CD40 ligand antagonist recently investigated in a phase 2 double-blind trial for the treatment of active moderate-severe rheumatoid arthritis (RA) with inadequate response to disease-modifying anti-rheumatic drugs (NCT04163991). We were delighted to speak to Dr. Alan J. Kivitz (Altoona Center for Clinical Research, Duncansville, PA, USA) to discuss the rationale for investigating dazodalibep in RA and the findings from the phase 2 study.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

The abstract ‘A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Patients with Rheumatoid Arthritis Having Inadequate Response to Conventional/Biological DMARDs.‘ (Abstract number: 2008) was presented at the ACR Convergence, November 10–14, 2022.

Questions

  1. What are the limitations of current disease-modifying anti-rheumatic drugs?
  2. What is dazodalibep and what is the rationale for its use in patients with rheumatoid arthritis?
  3. What were the eligibility criteria of your phase 2 study?
  4. What were the primary and secondary endpoints and how well were they achieved?
  5. On the basis of current findings, what is the potential of dazodalibep in the treatment paradigm for rheumatoid arthritis?

Disclosures: Alan J. Kivitz has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the ACR Convergence 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup